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Background: The impact of delayed clinical in-stent restenosis on the late re-inter-
ventions (RI) rate is currently unknown. To address this issue, we analyzed the long-
term clinical outcome in patients undergoing stent implantation for single de novo
lesions who were event-free after one year of follow-up, with an especial emphasis on
the rate of delayed restenosis and disease progression.
Methods: Retrospective analysis in patients who underwent single-vessel stenting
from January 2004 to December 2006 (N¼1385). In order to control for confounders,
we excluded patients with multivessel disease and patients who had RI during their
ﬁrst year of follow-up (N¼1108). From November 2012 to March 2013, we contacted
all patients included in the study (n¼277) and collected the following events: cardiac
death, RI, target lesion RI (TLR) and RI to other coronary segments due to disease
progression. Very late TLR was deﬁned as TLR events occurring after 3 years of
follow-up, while isolated TLR was deﬁned as TLR events occurring without RI due to
concomitant disease progression.
Results: Mean age was 60.310.1 years, 20.6 % were females, 16.2% diabetics and
72% had an acute coronary syndrome. 21.5% received a drug-eluting stent and 78.5 %
a bare-metal stent (50.2 % to the left anterior descending, 26% to the circumﬂex and
23.8% to the right coronary artery). Follow-up was available in 97.9% (92% with 7
years, mean follow-up 6.33.2 years). During follow-up, 89.2% of patients had at
least one non-invasive exercise test during follow-up (mean test performed per patient
3.21.8), 19.8% of those patients had a positive ischemic test at follow-up. 37.9 %
(n¼105) of patients underwent diagnostic coronary angiography, while 16% (n¼44)
required RI (Table). Cardiac death occurred in 2.8% of patients.
Conclusions: 1) Disease progression in patients with single vessel obstructive coro-
nary artery disease is an infrequent phenomenon but constitutes the dominant cause
for late RI. 2) Delayed clinical restenosis is rare. It's very late manifestation, typically
due to in-sent neoartherosclerosis, appears to have a very low clinical impact at least
until the seventh year of follow-up.N % Total % RI
Disease
progression
37 13.3 84
TLR 16 5.8 36.3
Very late TLR 7 2.5 15.9
Isolated TLR 7 2.5 15.9
Very late, isolated
TLR
3 1.1 6.8
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Background: In the drug-eluting stent era, in-stent restenosis (ISR) followed by a new
ISR recurrence, is deﬁned "resistant" ISR (R-ISR). This event represents a rare yet
challenging clinical problem. To date there are no published studies that evaluated the
best percutaneous treatment for these patients.
Methods: We identiﬁed 213 lesions in 201 patients treated with DES who presented
with R-ISR between 2003 and 2011 at our institution. The "balloon only" approach
with cutting, scoring or non-compliant balloon (n¼107, 53%) was compared with
coronary stent implantation (n¼94, 47%) in terms of target vessel revascularization
(TVR), target vessel failure (TVF), and a composite of major adverse cardiac event
(MACE) as death, myocardial infarction (MI) at 1-year.
Results: The baseline clinical characteristics were well balanced between two
percutaneous coronary intervention strategies. However the patients treated with
"balloon-only" presented with a worse baseline TIMI ﬂow (TIMI 0-1 13% vs. 5%,
P¼0.01), and had higher residual diameter stenosis post-PCI (19%  20 vs. 9%JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr11%, P<0.01). At 1-year follow-up, the rates of MACE, TVR, and TVF were not
signiﬁcantly different among the two strategies (Figure 1.).
Conclusions: Clinical outcomes after treatment of R-ISR with new stent implan-
tation does not appear to differ signiﬁcantly compared to a "balloon only"
technique.TCT-482
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Background: In the drug-eluting stent era, in-stent restenosis (ISR) followed by
ISR recurrence, represents a rare yet challenging clinical problem. The deﬁnition
and angiographic patterns of this phenomenon have not yet been reported.
Methods: We deﬁned "resistant" DES ISR (R-ISR) as the second occurrence of
ISR after initial successful treatment with DES. We identiﬁed 213 lesions in 201
patients treated with DES who presented with R-ISR between 2003 and 2011 at
our institution. We reviewed all angiograms to assess any patterns borne
from either the ﬁrst and second ISR episode as described by the Mehran
classiﬁcation.
Results: Patients with "resistant" ISR were more frequently male (72%) with
a mean age of 63 years. They presented with a very high frequency of diabetes
(56%), overweight (70%), and chronic kidney disease (35%). Most lesions were
bifurcation (55%) with moderate to severe calciﬁcation (58%). R-ISR presented
after 34 months from the ﬁrst procedure, with a focal pattern (10 mm in length)
in 78%, and diffuse pattern (>10 mm in length) in 22% of the patients. The rates
of all-cause mortality, MI, or target vessel failure (TVF) at 1-year were 4%, 3%,
and 18%, respectively. Patients with paclitaxel-eluting stent (PES) R-ISR showed
a higher rate of ischemic events compared with other type of stents at 1-year
follow-up (Table 1.).
Conclusions: Patients with "resistant" DES ISR comprise a very high-risk population
with suboptimal outcomes that are characterized by a high rate of ischemic adverse
events. R-ISR after PES appears to result in worse outcomes compared with other
DES.acts/POSTER/In-stent Restenosis and Stent Thrombosis B147
Overall
Paclitaxel
n=57 (29%)
Sirolimus
n=96 (49%)
Everolimus
n=44 (22%) P-value
R-ISR Presentation
Pattern 0.27
Focal 22% 11(19%) 26(27%) 7(16%)
Diffuse 78% 46(81%) 70(73%) 37(84%)
Time index
procedure to
R-ISR, months 
SD
3420 3521 4220 168 0.28
Time index
procedure to
ﬁrst-ISR, months
 SD
1816 1816 2318 74 0.52
R-ISR Treatment
Stent use 53% 48% 57% 52% 0.54
Outcome
Death 4% 9% 1% 2% 0.05
MI 3% 7% 2% 0% 0.12
TVF 18% 23% 17% 14% 0.58
MACE (Death,
MI, and TVF),
21% 32% 18% 16% 0.06
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Background: Previous studies have suggested that early ST (<30 days) may have
a different physiopathology as compared to late events occurring after this period. Our
objective was to investigate the predictors of ST in a large cohort of patients enrolled
in the prospective, single center DESIRE Registry.
Methods: A total of 4,790 pts (7,530 lesions) undergoing elective for emergency PCI
solely with DES (n¼8,058) as a default strategy were enrolled between May/02-Mar/
13. Clinical follow-up (FU) was performed at 1, 6 and 12 months and yearly up to 10
years (97.3%). ST was deﬁned according to the propositions of the Academic
Research Consortium.
Results: The overall incidence of ST was 2.4% (n¼111), given that 95% of patients
were ST-free up to 10 years FU (Kaplan-Meier estimate). Compared to those
without ST, pts with ST had a trend towards more diabetes (36 vs. 30.5%, p¼0.18)
and target lesion in saphenous vein grafts (SVG) (7.4 vs. 5.6, p¼0.10), and
signiﬁcantly more current smoking (41.2 vs. 30.1%, p¼0.02), clinical presentation
of recent MI (29.9 vs. 15.2%, p<0.001), moderate/severe lesion calciﬁcation (36.1
vs. 26.8%, p<0.001), poor left ventricle ejection fraction (<30%) (18.2 vs. 2%,
p¼0.02), multiple DES implanted (56.6 vs. 46.1%, p¼0.03), and residual stenosis
as assessed by QCA (5.0 vs. 3.7%, p¼0.001). In the multivariate model, inde-
pendent predictors of ST were recent MI (<72 hours) (HR 2.66, 95% CI 1.52-4.66,
p¼0.001), recent MI (3-30 days) (HR 1.89, 95% CI 1.08-3.29, p¼0.03), >1 DES
implanted (HR 1.89, 95% CI 1.28-2.80, p¼0.002), SVG (HR 2.21, 95% CI 1.29-
3.78, p¼0.004), and residual stenosis (HR 1.03 per % unit, 95% CI 1.00-1.05,
p¼0.03). Early ST was found in 12.6% of cases (14/111) and independent
predictors for this event were diabetes (OR 2.45, p¼0.01) and recent MI (<72
hours) (OR 3.65, p<0.001).
Conclusions: Early ST was a rare event and was signiﬁcantly associated with diabetes
and clinical presentation of recent MI (< 72 hours). When considering the overall
incidence of ST (2.4%), signiﬁcant independent predictors were recent MI (< 72
hours and between 3-30 days), multiple DES implanted, SVG and stent
underexpansion.
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Background: Stent thrombosis (ST) has been described as a rare event in current
drug-eluting stent (DES) era; however, its occurrence has been associated with rela-
tively high morbimortality. Our objective was to investigate the impact of second
generation DES on the occurrence of ST in daily clinical practice.
Methods: A total of 4,790 pts (7,530 lesions) undergoing elective for emergency PCI
solely with DES as a default strategy were enrolled between May/02-Mar/13. Clinical
follow-up (FU) was performed at 1, 6 and 12 months and yearly up to 10 years
(97.3%). Overall, a total of 8,058 DES were implanted including 1st generationB148 JACC Vol 62/18/Suppl B j October 27–November 1, 20(Cypher/Taxus) in 69% and 2nd generation (Xience/Promus/Resolute/Endeavor/Bio-
Matrix) in 31%, given that mean FU for pts treated with 1st vs. 2nd generation DES
were 5.32.6 vs. 1.11.0, respectively.
Results: Overall, mean age was 64 years, 31% had diabetes, 23% had previous
MI and 41% presented with acute coronary syndrome. Compared to pts treated
with 1st generation DES, those treated with 2nd generation DES had more dia-
betes (p<0.001), multivessel disease (p<0.001), and multiple DES implanted
(p<0.001), but angiographic success was similar in both groups (>99%). The
occurrence curve for ST (ARC) up to 2 years FU with landmark analysis at 1
year is shown in the Figure.Conclusions: Compared to 1st generation DES, the use of 2nd generation DES was
associated with a non-signiﬁcant trend towards less occurrence of ST up to 2 years
FU, given that there were no very late ST found with 2nd generation DES.
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Background: In the ﬁrst generation drug-eluting stent (DES) era, it had reported that
clinical outcome of paclitaxel-eluting stent (PES) deployment was better than siroli-
mus-eluting stent. But clinical outcome of PCI with second generations DES was not
established. Our aim was to investigate the clinical outcomes of hemodialysis (HD)
patients after PCI with DES.
Methods: In 6298 consecutive cases which underwent PCI with DES between April
2007 and June 2012, 182 consecutive patients (247 lesions) on HD patients were
treated with PES (P group: 93 patients, 117 lesions), everolimus-eluting stent (E
group: 54 patients, 78 lesions) or biolimus-eluting stent (B group: 35 patients, 52
lesions) implantation and were follow up to 8 months. The primary endpoints were
angiographic outcomes and MACE (death, myocardial infarction, CABG, target
lesion revascularization: TLR).
Results: Clinical follow up was obtained on all patients. Angiographic follow up
was obtained in 201 lesions (81.4%). No signiﬁcant difference was detected in the
baseline demographic, angiographic, and lesion characteristics. In eight month
follow-up, the mean values of late lumen loss (P group: 0.50.8mm, E:
0.60.8mm, B: 1.00.6mm; p¼0.01), TLR (P group: 9.3%, E: 15.4%, B: 28.9%;
p<0.01) and MACE (P group: 12.7%, C: 19.2%, B: 28.9%; p¼0.04) in P group
was the lowest in these groups. In multivariate analysis, predictors of TLR were
diabetes mellitus (OR: 2.7, 95%CI: 1.1-7.0, p¼0.025), BES deployment (OR: 3.4,
95%CI: 1.5-7.5, p¼0.0027) and product of serum calcium and phosphorus>38
(OR: 3.6, 95%CI: 1.6-8.9, p¼0.0016).
Conclusions: In PCI with DES for HD patients, second generation DES hasn't
improved clinical outcomes. PES deployment is still usefulness today.13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
